Ionis Pharmaceuticals Inc (IONS) Chairman Sells $1,100,220.00 in Stock

Ionis Pharmaceuticals Inc (NASDAQ:IONS) Chairman Stanley T. Crooke sold 22,000 shares of the company’s stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $50.01, for a total transaction of $1,100,220.00. Following the completion of the sale, the chairman now directly owns 58,014 shares in the company, valued at $2,901,280.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ionis Pharmaceuticals Inc (NASDAQ:IONS) traded down $0.54 during trading on Friday, reaching $49.48. 1,067,600 shares of the company’s stock were exchanged, compared to its average volume of 1,050,267. The firm has a market cap of $6,200.00, a price-to-earnings ratio of 353.43 and a beta of 2.86. Ionis Pharmaceuticals Inc has a 12 month low of $37.26 and a 12 month high of $65.51. The company has a debt-to-equity ratio of 1.50, a quick ratio of 6.21 and a current ratio of 6.25.

A number of institutional investors have recently added to or reduced their stakes in IONS. Russell Investments Group Ltd. lifted its holdings in Ionis Pharmaceuticals by 21.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 20,077 shares of the company’s stock worth $1,021,000 after buying an additional 3,538 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in Ionis Pharmaceuticals by 17.4% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 367,550 shares of the company’s stock worth $18,698,000 after buying an additional 54,587 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Ionis Pharmaceuticals by 30.9% during the 2nd quarter. SG Americas Securities LLC now owns 6,315 shares of the company’s stock worth $321,000 after buying an additional 1,489 shares in the last quarter. Legal & General Group Plc lifted its holdings in Ionis Pharmaceuticals by 9.7% during the 2nd quarter. Legal & General Group Plc now owns 44,480 shares of the company’s stock worth $2,262,000 after buying an additional 3,944 shares in the last quarter. Finally, BNP Paribas Arbitrage SA lifted its holdings in Ionis Pharmaceuticals by 29.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 17,252 shares of the company’s stock worth $878,000 after buying an additional 3,946 shares in the last quarter. Institutional investors own 91.40% of the company’s stock.

A number of brokerages have weighed in on IONS. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price objective on shares of Ionis Pharmaceuticals in a research report on Tuesday, October 17th. BMO Capital Markets restated an “outperform” rating and set a $69.00 price target on shares of Ionis Pharmaceuticals in a research report on Monday, October 2nd. Barclays reduced their price target on shares of Ionis Pharmaceuticals from $55.00 to $52.00 and set an “equal weight” rating for the company in a research report on Thursday, September 21st. BidaskClub downgraded shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, December 22nd. Finally, Zacks Investment Research cut shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $50.31.

ILLEGAL ACTIVITY NOTICE: “Ionis Pharmaceuticals Inc (IONS) Chairman Sells $1,100,220.00 in Stock” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/05/ionis-pharmaceuticals-inc-ions-chairman-sells-1100220-00-in-stock.html.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply